Enzo Biochem, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stockholders' equity (Details)

Stockholders' equity (Details) (USD $)	6 Months Ended		12 Months Ended				6 Months Ended		12 Months Ended											12 Months Ended
Stockholders' equity (Details) (USD $)	Jan. 17, 2013	Jan. 31, 2013	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011	Mar. 28, 2013	Jan. 17, 2013 Vests Over Two Years [Member]	Jan. 17, 2013 Vests Over Three Years [Member]	Jul. 31, 2013 Common Stock [Member]	Jul. 31, 2013 Treasury Stock [Member]	Jul. 31, 2012 Treasury Stock [Member]	Jul. 31, 2011 Treasury Stock [Member]	Jul. 31, 2013 Additional Paid-in Capital [Member]	Jul. 31, 2012 Additional Paid-in Capital [Member]	Jul. 31, 2011 Additional Paid-in Capital [Member]	Jul. 31, 2013 1999 Plan [Member]	Jul. 31, 2013 2005 Plan [Member]	Jul. 31, 2013 2011 Plan [Member]	Jan. 14, 2011 2011 Plan [Member]	Jul. 31, 2013 Minimum [Member]	Jul. 31, 2013 Maximum [Member]
Stockholders' equity (Details) [Line Items]
Common Stock, Par or Stated Value Per Share (in Dollars per share)			$ 0.01	$ 0.01		$ 0.01
Maximum Offering Price Under Sales Agreement						20,000,000
Percentage of Commission Payable on Equity Offering			3.00%
Stock Issued During Period, Shares, New Issues									906,715
Average Sale Price of Stock (in Dollars per share)			$ 2.26
Proceeds from Issuance of Common Stock (in Dollars)			$ 1,825,000
Stock Offering and Commissions Expenses (in Dollars)			224,000
Stock Issued During Period Shares Acquisition Earn Out				275,000
Fair Value of Stock Issued for Acquisition Earn Out (in Dollars)				500,000
Stock Issued During Period, Shares, Treasury Stock Reissued										(216,556)	(233,458)	(173,834)
Payments of Stock Issuance Costs (in Dollars)			643,000	649,000	690,000
Stock Issued During Period, Value, Treasury Stock Reissued (in Dollars)			616,000	649,000	690,000					3,074,000	3,313,000	2,467,000	(2,458,000)	(2,664,000)	(1,777,000)
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																2,312,356	1,000,000
Share Based Compensation Arrangement by Share Based Payment Award Number of Additional Awards to be Granted																0	0
Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Units																			3,000,000
Number of Shares of Common Stock Remain Available for Issuance as Option for Plan Termination																		0
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant																		2,322,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years																			2 years	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value (in Dollars)			0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	336,817		336,817
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)	$ 2.88		$ 2.88
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures							247,672	89,145
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	3 years 109 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	60.80%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	0.45%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments (in Dollars)	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares		0
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights		The Awards vest upon the recipient's continued employment or director service ratably over either two, three or four years.